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Abstract 
Information on acute systemic toxicity represents a standard requirement within several pieces of chemicals legislation in 
the EU. One of the main drivers of conducting the test is classification and labelling. Currently, only in vivo tests are 
accepted by regulatory bodies and most of the standard tests use lethality as endpoint. Based on an assessment of the 
regulatory needs and the scientific state-of-the art in the area, EURL ECVAM considers that efforts should be directed 
towards a) the reduction and replacement of animal tests for the identification and classification of acute systemic 
toxicity, and b) the refinement of in vivo studies. Consideration should be given to collecting, organising and applying 
mechanistic knowledge related to this endpoint, to provide a strong mechanistic basis for the design and validation of 
integrated prediction models. EURL ECVAM proposes to evaluate promising components of integrated approaches for 
testing and assessment (IATA), including the better use of existing alternative methods, such as mechanistically relevant 
in vitro assays. Information on repeated dose toxicity might also be useful in supporting classification and labelling for 
acute systemic toxicity. One clear target is minimising animal use for satisfying information requirements for acute 
systemic toxicity in relation to the 2018 REACH registration deadline. The aims and objectives underpinning the EURL 
ECVAM strategy can only be achieved through the coordinated and concerted efforts of all stakeholders. 
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Executive summary 
The assessment of acute systemic toxicity is a component of the safety assessment of 
substances in the context of EU and international legislation. Information requirements vary 
depending on the type of substance subject to regulation and the region. In preclinical drug 
development, however, these studies are no longer required by default to support first 
clinical trials and their value for overdose and poisoning assessment has been questioned. 
One of the main drivers for the assessment of acute systemic toxicity is classification and 
labelling. Currently only data derived from animal tests are accepted by regulatory bodies, 
which include reduction and refinement methods for the oral and inhalation route. Most of 
the standard in vivo tests use lethality as the endpoint, even though this has been widely 
criticised both on animal welfare and scientific grounds. Cell-based methods, and in 
particular in vitro cytotoxicity assays, are recognised as additional tests that can be used for 
estimating the initial doses for tests in vivo. However, to date, this approach has not been 
widely taken up in practice and its contribution to reducing animal numbers has been 
questioned. The development of mechanistically-based alternative methods and strategies 
for acute systemic toxicity is hampered by the limited understanding of the key acute toxicity 
pathways in humans. 
This report outlines the strategy proposed by the European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL ECVAM) for achieving a 3Rs impact in the area of acute 
systemic toxicity assessment. The EURL ECVAM strategy is based on an assessment of the 
regulatory needs for this health effect and the scientific state-of-the art in the area. Apart 
from specifying aims and associated objectives to progress this field, the strategy is also 
intended to provide a framework for the prioritisation of alternative test methods submitted 
to EURL ECVAM for validation. 
EURL ECVAM considers that efforts in this area should be directed towards the reduction and 
eventual replacement of animal tests for the identification and classification of acute 
systemic toxicity. Consideration should be given to collecting and organising mechanistic 
knowledge related to acute systemic toxicity in order to improve the design and validation of 
predictive models and approaches such as Integrated Approaches to Testing and 
Assessment. In this regard, EURL ECVAM proposes to explore scientific options to support the 
waiving of acute systemic toxicity testing, including the better use of existing alternative 
methods such as mechanistically relevant in vitro assays, as well as existing information on 
repeated dose toxicity. Efforts should also continue in the refinement of in vivo studies when 
they are necessary. The implementation of this strategy will rely not only on the efforts of 
EURL ECVAM but on the collective and coordinated contribution of a wide range of 
stakeholders. 
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Abbreviations and Glossary Terms 
3Rs Replacement, Reduction, Refinement 
ADME Adsorption, Distribution, Metabolism and Excretion 
AOP Adverse Outcome Pathway 
ACuteTox  Optimisation and Prevalidation of an In Vitro Test Strategy for Predicting 
Human Acute Toxicity 
CARACAL Competent Authorities for REACH and CLP 
CLP Classification, Labelling and Packaging of Substances and Mixture 
COSMOS  Integrated In Silico Models for the Prediction of Human Repeated Dose 
Toxicity of COSMetics to Optimase Safety 
DNEL Derived No-Effect Level 
EPAA European Platform for Alternatives to Animal Testing 
ECHA European Chemicals Agency 
EU European Union 
EURL ECVAM European Union Reference Laboratory for Alternatives to Animal Testing 
FCP Fixed Concentration Procedure 
FN False Negative 
FP False Positive 
GLP Good Laboratory Practice 
HSI Humane Society International 
IATA Integrated Approaches to Testing and Assessment 
LC50  The concentration to kill 50% of the population (median lethal concentration) 
LD50  Single oral/dermal dose to kill 50% of a population (median lethal oral/dermal 
dose) 
NC3Rs National (UK) Centre for Refinement, Reduction, Replacement 
NGO Non-governmental organisation 
NIH National Institute of Health 
NOAEL No Observed Adverse Effect Level 
NRU Neutral Red Uptake 
OECD Organisation for Economic Co-operation and Development 
PBTK Physiologically-Based Toxicokinetics 
QSAR Quantitative Structure-Activity Relationship 
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals 
SEURAT-1  Safety Evaluation Ultimately Replacing Animal Testing – phase 1 
TG Test Guideline 
TN  True Negative 
TP True Positive 
TK Toxicokinetics 
tpy Tonnes per year 
UN GHS United Nations Globally Harmonised System of Classification and Labelling 
UK United Kingdom 
WNT OECD Working Group of National Coordinators for the Test Guideline Program 
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1. Introduction 
Acute systemic toxicity comprises the general adverse effects that occur after a single or 
multiple exposure of an animal to a substance within 24 hours and during an observation 
period of at least 14 days. The substance may be administered orally, by inhalation or 
dermally. 
The assessment of acute systemic toxicity is one component in the safety evaluation of 
substances and represents a standard information requirement within several pieces of EU 
chemicals legislation, including the Regulation on Classification, Labelling and Packaging 
(CLP) of substances and mixture (EU, 2008a), the Regulation concerning the Registration, 
Evaluation, Authorisation and Restriction of chemicals (REACH) (EU, 2006), the Biocidal 
Products Regulation (EU, 2012), the Plant Protection Products Regulation (EU, 2009a) and 
the Cosmetic Products Regulation (EU, 2009b). Currently, only in vivo tests are accepted by 
regulatory bodies. However, in vivo acute systemic toxicity studies are prohibited for 
cosmetic substances and products (EC, 2009b). Following the provisions of the REACH 
Regulation and its Annex XI, weight of evidence, qualitative or quantitative structure-activity 
relationship (QSAR) models, information from structurally related substances (grouping or 
read-across), and in vitro tests can be proposed by the Registrant instead of standard in vivo 
data, provided that adequate documentation and coverage of the standard parameters and 
observations are included in the dossier submitted for evaluation to the European Chemicals 
Agency (ECHA). 
In preclinical drug development, these studies are no longer required by default to support 
first clinical trials in man. In many circumstances, the information needed can be obtained 
from other tests that use non-lethal endpoints and that are already carried out as part of 
the drug development process. Further, their value for Phase III pharmacological overdose 
and poisoning assessment has been questioned (Robinson et al., 2008; ICH, 2009; Chapman 
et al., 2010). Information on data requirements according to the different regulations is 
included in Annex I. 
For the oral route the in vivo studies include three refinement and reduction methods 
described in OECD test guideline (TG) 420 (fixed dose procedure) and EU Test method B.1 
bis, OECD TG423 (acute toxic class method) and EU Test method B.1 tris, and OECD TG425 
(up and down procedure) (OECD, 2001a, b, c; EU, 2008b). For acute dermal toxicity, the only 
guideline available is the classical dermal LD50 study (TG402, OECD, 1987a; EU Test Method 
B.3, EU, 2008b). For inhalation toxicity there is a revised version of the classical LC50 study 
(TG403, OECD, 2009a; EU Test Method B.2, EU, 2014) and the acute toxic class method 
(TG436, OECD, 2009b; EU Test Method B.52; EU, 2014). Moreover, TG420, TG423, TG425 
and TG436 use the fewest animals.  
The endpoint measured in the majority of these standard assays is animal morbidity or 
death while evident signs of toxicity (clear signs of toxicity indicate that exposure to the next 
highest concentration would cause severe toxicity in most animals within the observation 
period) is only used in the oral fixed dose procedure. The use of lethality as an endpoint has 
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long been criticised on animal welfare grounds, while the utility of the actual data generated 
by acute toxicity tests with regard to their ultimate purpose, namely to predict the human 
hazard potential of substances, has also been questioned. Moreover, Directive 2010/63/EU 
on the protection of animals used for scientific purposes states under point recital (14): 
"The methods selected should avoid, as far as possible, death as an end-point due to the 
severe suffering experienced during the period before death. Where possible, it should be 
substituted by more humane end-points using clinical signs that determine the impending 
death, thereby allowing the animal to be killed without any further suffering." 
One of the main purposes of conducting these in vivo tests is to categorise substances 
according to their potential hazard, the dose required to cause toxicity, and to communicate 
specific information on the hazard concern to workers, emergency responders and 
consumers (i.e. to support regulatory classification and labelling decisions). This has been 
confirmed by surveys carried out by the pharmaceutical industry (Robinson et al., 2008) and 
by the European Partnership for Alternative Approaches to Animal (EPAA) covering other 
sectors (Seidle et al, 2010).  
The currently applied classification systems are based on arbitrary cut-off values for LD50 
which are then used to estimate human acute toxicity. Within the EU, the CLP Regulation is 
used to classify chemicals on the basis of acute oral toxicity into four toxicity categories 
(categories 1 to 4 of the United Nations Globally Harmonised System of Classification and 
Labelling - UN GHS, see tables 1 and 2 in Annex I). CLP itself does not set information 
requirements for health hazards and thus classification may be carried out on the basis of 
available information (EU, 2008a). 
Additional scientific drivers for conducting these studies, such as dose setting for repeated 
dose studies, can be obtained from other study types such as the dose escalation studies 
carried out to identify maximum tolerated dose (Zbinden and Flury-Roversi, 1981; Robinson 
et al, 2008; Seidel et al, 2010). 
Human reference values such as the acute reference dose, the acceptable daily intake and 
acute systemic Derived No-Effect levels (DNELs) for risk assessment are usually derived 
from repeat dose studies (see Annex I, section 1.2 and table 3). Acute human poisoning is 
treated on the basis of actual clinical symptoms rather than rat LD50 values. Only if no other 
data for systemic toxicity are available then acute systemic toxicity data may be useful for 
classification/labelling based risk mitigation measures (e.g. setting of occupational exposure 
limits and chemical emergency response planning).  
Acute systemic toxicity after oral, dermal or inhalation exposure requires that the substance 
becomes bioavailable to a certain extent at the target site. This means that kinetic factors, 
and importantly absorption, are key determinants of toxicity as indicated in the EURL ECVAM 
strategy report on toxicokinetics (Bessems et al, in preparation). In addition, if the damage 
involves interference with homeostatic mechanisms, non-exposed tissues and vital organs 
can also be affected. For example, respiratory depression leading to death may be due to 
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depression of the central nervous system rather than a direct effect on the respiratory 
system (Gennari et al., 2004).  
Basal cytotoxicity is certainly a key event in many prevalent toxicological modes-of-action 
associated with acute health effects. It covers many general mechanisms of toxicity 
common to most cell types that can lead to organ failure, including for example, disruption 
of membrane structure or function, inhibition of mitochondrial function, disturbance of 
protein turnover, and disruption of metabolism and energy production. The mechanisms 
involved in cytotoxicity and susceptible functions compromised in organ failure have been 
discussed in numerous papers (Gennari et al, 2004; NIH, 2009; Hartung, 2008, 2014). 
The possibility to use cell-based methods to predict acute oral toxicity has been extensively 
investigated. In this regard, in vitro cytotoxicity assays have been developed and evaluated 
against in vivo oral LD50 data (correlative approaches) within the context of several 
international projects (Ekwall, 1999; Halle, 2003; NIH, 2006, Prieto et al., 2013a, b). To date 
cytotoxicity assays have been considered only as additional tests that can be used for 
estimating the initial doses for acute oral systemic toxicity tests in vivo (OECD, 2010). It 
appears, however, that this approach has not been widely taken up in practice. The 
usefulness of the 3T3 NRU assay for predicting the in vivo classification and for predicting 
the starting dose for the subsequent in vivo test was also evaluated by Schrage et al. 
(2011). Their analysis demonstrated a low overall accuracy of the 3T3 NRU in predicting the 
acute oral toxicity categories (NIH, 2006) and on this basis, the authors questioned its 
contribution to reducing animal numbers when used to estimate the starting dose for the 
animal test.  
Nevertheless, the evidence also indicates that the 3T3 NRU basal cytotoxicity assay can be 
used to support the identification of negatives (non-classified substances), with the caveat 
that due to the limitations of this test method, results should always be used in combination 
with other information sources to build confidence in the decision not to classify a substance 
for acute oral toxicity. As stated in a recent EURL ECVAM Recommendation, the applicability 
domain of the 3T3 NRU needs further characterisation (EC-EURL ECVAM, 2013).  
In addition to using basal cytotoxicity, it will also be important to identify cell types and in 
vitro endpoints that are indicative of cell-type specific toxicities, with a view to integrating 
such endpoints into Integrated Approaches to Testing and Assessment (IATA). For instance, in 
safety pharmacology studies, the cardiovascular, respiratory and central nervous systems 
are assessed in a core battery since they are considered vital organs or systems, the 
functions of which are acutely critical for life (ICH, 2000). Thus the information provided by 
combinations of relevant in vitro assays is expected to have an important contribution in 
future IATA. 
The purpose of this document is to present the EURL ECVAM strategy to avoid, reduce and 
refine animal testing for acute toxicity hazard identification and classification. The focus is 
on acute effects that are systemic in nature and, therefore, local effects are not covered. The 
ultimate aim is to propose solutions that can satisfy information requirements under several 
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pieces of EU legislation and that can also be considered by the OECD in the context of 
globally harmonised approaches for the assessment of acute systemic toxicity. 
The strategy is intended to be inclusive and as such, its implementation will rely on 
cooperation between EURL ECVAM and various stakeholders and the coordination of 
complementary initiatives addressing the strategic aims and related objectives outlined here. 
 
 
2. Strategy to avoid, reduce and refine the use of animals in the 
assessment of acute systemic toxicity  
In those industrial sectors in which acute systemic toxicity testing is legally required, the 
data are primarily used to support regulatory decisions on classification and hazard 
labelling1. Therefore, EURL ECVAM proposes that efforts should be directed towards the 
reduction and eventual elimination of animal tests for the identification and classification of 
acute systemic toxicity toxicants.  
 
The following two key aims are proposed: 
 
Strategic Aim 1:  Reduction and replacement of animal testing in the assessment of 
acute systemic toxicity  
 
Strategic Aim 2:  Refinement of animal studies 
 
The objectives and related activities summarised in Figure 1 have been identified as being 
necessary to achieve these aims, the realisation of which is expected to have a significant 
impact on regulatory testing in different industrial sectors. 
                                                        
1 For extremely hazardous (US) or dangerous (EU) substances the data can be used to derive acute DNELs or 
acute exposure guideline levels (AEGLs) if exposure occurs via accident or contaminated land. 
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Figure 1. EURL ECVAM strategy to avoid, reduce and refine animal use in the assessment of 
acute toxicity (IATA - Integrated Approaches to Testing and Assessment; PBTK -
Physiologically-Based Toxicokinetics). 
 
 
2.1 Strategic Aim 1: Reduction and replacement of animal testing in 
the assessment of acute systemic toxicity 
The development of IATA for hazard-based classification is expected to have an impact in 
terms of replacement and reduction of animal testing. However, as noted above, the 
development of IATA in this area is hampered by the lack of sufficient mechanistic 
understanding of the numerous toxicity pathways and/or modes-of-action that lead to acute 
systemic toxicity. An important consideration is then to improve the theoretical 
understanding of acute systemic toxicity since this would provide a strong mechanistic basis 
for the design and validation of integrated prediction models.  
The EU FP6 ACuteTox project aimed to develop a non-animal testing strategy for predicting 
human acute oral toxicity by evaluating and combining cytotoxicity assays, organ-specific 
toxicity assays, and biokinetic/metabolism methods (Kinsner-Ovaskainen et al., 2013). The 
project showed the added value of combining the prediction results gained from in vitro 
cytotoxicity assays with information on target organ alerts identified by specific in vitro 
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assays (e.g. neurotoxicity), which helped reduce the number of under-predictions generated 
by the cytotoxicity assay alone (Prieto et al., 2013a; Zurich et al., 2013).  
There are several ongoing activities that, although not directly focused on acute systemic 
toxicity, could contribute to our understanding of toxicological modes-of-action and also 
provide innovative methodologies and tools for acute toxicity testing. These are the EU FP7 
SEURAT-1 ('Safety Evaluation Ultimately Replacing Animal Testing' - first phase) research 
initiative (http://www.seurat-1.eu/), focused on alternatives for repeat dose toxicity testing, 
the Tox21 programme (http://www.epa.gov/ncct/Tox21/), the ToxCast screening programme 
(http://www.epa.gov/ncct/toxcast/) and the work undertaken by the Hamner Institute for 
Chemical Safety Sciences (http://www.thehamner.org/institutes-centers/institute-for-
chemical-safetysciences/) in the USA. 
The gathering and targeted generation of mechanistic knowledge related to systemic toxicity 
should remain a continuous endeavour within the toxicological community. However, the 
impact of this effort can be enhanced through the adoption of a more systematic and 
structured approach to the integration, curation and reporting of such knowledge through the 
use of the OECD's Adverse Outcome Pathway (AOP) framework and related guidance (OECD, 
2013). Provision of this knowledge through the AOP Knowledge Base (www.aopkb.org) will 
benefit both scientific and regulatory communities in the development, validation and 
eventual acceptance of alternative approaches for assessing acute systemic health effects.   
Taking a fundamentally knowledge-driven approach which is both inspired and supported by 
empirical evidence, EURL ECVAM proposes the pursuit of the following objectives within this 
strategic aim:  
 
Objective 1.1. Development and optimisation of mechanistically relevant alternative methods 
for use within IATA 
EURL ECVAM proposes to explore options for making better use of existing in vitro and in 
silico methods by investing in the systematic and comprehensive characterisation of their 
predictive value, possible limitations and applicability domain. 
Following on from experience gained during the validation of the 3T3 NRU assay (EC-EURL 
ECVAM, 2013), the ability to rationalise true/false predictions generated by cytotoxicity 
assays and to complement the test results with other types of relevant information (e.g. 
absorption, distribution, metabolism, and excretion (ADME)/toxicokinetics (TK) properties or 
association with selective mechanisms-of-action that cause organ-specific effects) would 
provide the basis for a more accurate identification of positive and negative chemicals 
compared with the use of cytotoxicity assays alone. An example of a tiered assessment 
approach based on such rationale is illustrated in Figure 2. A negative prediction from the 
3T3 NRU cytotoxicity assay (i.e. estimated oral LD50 value above the threshold limit of 2000 
mg/kg of body weight) would need to be supported with evidence of an absence of 
bioactivation of the compound, by excluding specific modes-of-action indicative of acute 
organ-specific toxicity and/or by excluding in vitro kinetic processes (e.g. evaporation, 
 12 
absorption to the plastic, or binding to proteins present in the medium) that could 
significantly influence the effective (free) concentrations tested. Predicting the ADME 
properties of a compound in the body could also help identify false positive results derived 
from in vitro cytotoxicity data, due for example to limited in vivo absorption or rapid 
elimination of the compound (metabolism if it is deactivating and excretion). In the validation 
of such assessment approaches however, misclassifications related to predictions using 
alternative methods should be interpreted in the light of the imprecision of the in vivo 
method (Hoffmann et al., 2010). 
The use of chemoinformatic methods should be explored to identify structural features 
associated with specific effects at molecular, cellular and tissue levels. It is anticipated that 
this information will be used in supporting grouping and read-across, guiding cell-specific in 
vitro testing, and complementing the use of in vitro cytotoxicity assays.  
With a view to supporting such efforts, EURL ECVAM will use the 3T3 NRU cytotoxicity 
dataset available in-house as a starting point. However, consideration will be given to 
expand the dataset with under-represented chemical use-categories (e.g. biocides, 
agrochemicals) and toxicity categories (i.e. GHS category 1 and category 2). The intention is 
to make the dataset publicly available in order to allow complementary investigations by 
stakeholders, for example, to evaluate other promising in vitro assays to understand their 
applicability domain and the value of information derived from them.  
Based on these efforts, it will be helpful to develop practical guidance, with illustrative case 
studies, on how to optimally combine in vitro assays with other information sources within 
IATA for the purposes of hazard identification. This will be relevant for the REACH 2018 
registration deadline and in particular for substances imported or produced at 1-10 tonnes 
per year (REACH Annex VII) for which information from acute oral toxicity studies is required 
but data on repeated dose toxicity may be lacking (see Objective 1.2 below). Under this low 
tonnage band, information on repeated dose toxicity is not required and therefore often 
unavailable (see Annex 1, section 1.2). Because the greatest number of substances is 
expected to be registered for this deadline and a testing proposal for an acute toxicity study 
is not required, development of this guidance is urgently needed. Such guidance would also 
be very valuable for the implementation of the EU Regulations on CLP, on Biocidal Products 
and on Plant Protection Products. 
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Figure 2. Possible outcomes of the 3T3 NRU cytotoxicity assay when used to identify 
chemicals that are not classified on the basis of acute oral toxicity (TP = true 
positive result; FP = false positive result; FN = false negative result; TN = true 
negative result). 
 
 
Objective 1.2. Explore the use of repeated dose studies to support classification and labelling 
for acute oral systemic toxicity  
Information on repeated dose toxicity, if available, might be very useful for inferring acute 
effects. In-house preliminary work by Bulgheroni and colleagues (2009) evaluated the 
possibility to identify non-classified substances (i.e. those with an oral LD50 > 2000 mg/kg) 
from the results of 28-day repeated dose studies. The findings showed that a 28-day NOAEL 
threshold of 200 mg/kg b.w. allowed the correct identification of 63% (913/1436) of the 
non-toxic substances considered.  
Building on this work, EURL ECVAM is exploring the use of data from repeated dose studies 
as a means of gaining information on toxic effects and supporting classification and labelling 
for acute oral toxicity. In order to obtain input from multiple sectors, EURL ECVAM has 
launched a survey aimed at gathering additional information and expert opinion in the field 
of acute systemic toxicity testing and in particular regarding the possibility to conclude on 
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acute systemic toxic effects from systemic repeated dose studies. The questionnaire has 
been sent to experts from authorities, academia, industry, NGO's and was publically 
accessible via the EU survey website until the end of November 2014. 
The compilation of a more extensive database of acute and repeated dose study results 
using reliable information from several available sources would be very beneficial. Analysing 
such data would be highly relevant for the REACH 2018 registration deadline, in particular 
for substances imported or produced at 10-100 tonnes per year (Annex VIII) for which 
repeated dose 28 day study data are also required (see Annex 1, section 1.2). Likewise, 
waiving acute toxicity tests based on the interpretation of repeated dose data for satisfying 
information requirements regarding acute effects will be relevant for the classification of 
active substances used in biocides and plant protection products. 
 
Objective 1.3. Route-to-route, in vitro to in vivo and inter-species extrapolation  
Route-to-route extrapolation offers a solid opportunity to reduce animal testing. 
Extrapolation from in vivo oral toxicity to dermal toxicity is generally expected to be 
protective (Moore et al., 2013) and thus questions the necessity to test for acute dermal 
toxicity when oral data already exists. Extrapolation from the oral to the inhalational route 
has been investigated but is less well established (Seidle et al, 2011). 
As part of its involvement in the SEURAT-1 initiative (and in particular the COSMOS project), 
EURL ECVAM is involved in work aimed at exploring the use of in silico models in route-to-
route (Gajewska et al, 2014a,b) and in vitro to in vivo extrapolations (Pery et al., 2013). 
Regarding the possibility for inter-species extrapolation and the importance of toxicokinetics, 
Scholz et al (2014) have recently evaluated the possibility to use the LC50s of the fish embryo 
acute toxicity test to predict acute mammalian toxicity categories. In their analysis, they took 
into consideration the impact of species sensitivity, protocol differences and the chorion as 
potential source of variability/error. The results showed only a weak correlation of fish 
embryo LC50 and rat oral LD50 and the inability to effectively predict GHS oral acute toxicity 
categories. The authors claimed differences of exposure and pharmacokinetics of both 
systems as the limiting factors.  
 
Objective 1.4. Development of scientifically based waiving arguments to avoid animal testing 
in acute systemic toxicity studies 
The European Commission has recently received proposals by the European Platform for 
Alternatives to Animal Testing (EPAA) and the Humane Society International (HSI) to modify 
REACH standard information requirements for acute toxicity. With regard to the acute dermal 
toxicity test, the EPAA proposal suggested the waiving of a dermal study if an oral LD50 is 
greater than 2000 mg/kg b.w. (i.e. not classified by the oral route). This is supported by 
publications showing that the overall classification is rarely driven by the dermal 
classification and substances which are not classified by the oral route are also not classified 
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for the dermal route (Indans et al, 1998; Thomas & Dewhurst, 2007; Creton et al, 2010; 
Seidle et al, 2011; Moore et al, 2013).  
Other elements of the proposals included recommendations to: a) request acute toxicity 
testing by routes other than oral only if certain criteria are fulfilled; b) take toxicity and 
bioavailability into account when deciding whether other routes should be tested; c) test 
dermal absorption before performing an acute dermal toxicity study; d) establish quantitative 
criteria to assess the need for acute toxicity testing via the inhalation route; and e) make the 
acute toxic class method the preferred method for acute toxicity testing via the inhalation 
route. These proposals have been discussed by the Competent Authorities for REACH and CLP 
(CARACAL) and at the July 2014 meeting they agreed to amend REACH Annex VIII (point 
8.5.3) so that substances that have not shown oral acute toxicity up to a limit dose of 
2000mg/kg body weight would not require dermal data. 
A project proposal submitted to the OECD by the USA and Canada aims to develop guidance 
for waiving or bridging mammalian acute toxicity tests, including acute systemic toxicity 
testing, for pesticides and biocides. The project was approved by the OECD Working Group of 
National Coordinators for the Test Guidelines Programme (OECD WNT) and invites the 
collaboration between several stakeholders. 
 
 
2.2 Strategic Aim 2: Refinement of animal studies for acute systemic 
toxicity 
The use of death as an endpoint for acute toxicity testing is a matter of concern among 
many scientists and regulators, not only because of the direct negative impact on animal 
welfare but also because it has little value in risk assessment and risk management (e.g. 
derivation of acute DNELs, establishment of acute reference doses) or in deciding treatment 
of symptoms in human acute toxicity (Chapman et al., 2010; Creton et al., 2010; EPAA, 
2012). As encouraged by the Directive 2010/63/EU (EU, 2010) and OECD Guidance 
Document 19 (OECD, 2000), the substitution of lethality by more humane clinical signs 
indicative of imminent death would be beneficial on both scientific and animal welfare 
grounds. At present, only the oral fixed dose procedure (OECD TG420) uses observations of 
evident clinical signs of toxicity to provide a range estimate of the LD50, thus avoiding death 
as endpoint. 
For the assessment of acute oral and inhalation toxicity there are alternative in vivo methods 
available that represent refinement and/or reduction approaches to testing compared to the 
deleted oral TG401 (OECD, 1987b) and the standard inhalation TG403 (OECD, 2009a). 
However, for the assessment of acute dermal toxicity the only guideline currently available is 
the classic dermal LD50 study (TG402; OECD, 1987a) that uses lethality as the primary 
endpoint and requires an average number of animals between 10 (limit test) and 30. 
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Objective 2.1. Continue efforts to avoid the use of lethality as endpoint for acute systemic 
toxicity testing 
During an EPAA expert meeting organised in 2012 to review methods used to evaluate acute 
human toxicity of chemicals and agrochemicals, the need to move away from lethality as the 
endpoint for acute systemic DNEL derivation was emphasised, not only for obvious ethical 
reasons but also because of the need to reduce, as far as possible, the level of uncertainty in 
extrapolating the dose descriptor for DNEL to the human health risk assessment 
(http://ec.europa.eu/enterprise/epaa/index_en.htm). 
An EPAA project on acute systemic toxicity is ongoing and experts are discussing how to 
address classification and labelling requirements (all routes of exposure) by alternative 
means. This project is expected to provide useful insight towards the development of waiving 
arguments (objective 1.4) and the integration of 'evident toxicity' instead of death as an 
endpoint. In addition, the use of cytotoxicity assays, chemical grouping and read-across, 
QSARs and data from in vivo dose range-finding studies to satisfy regulation is also 
envisaged.  
The UK's National Centre for the Replacement, Refinement and Reduction of Animals in 
Research (NC3Rs) is leading activities to support the acceptance at OECD level of the fixed 
concentration procedure (FCP) for acute inhalation studies (OECD TG433). The proper use of 
clinical signs instead of lethality for classification and labelling purposes is the basis of the 
fixed concentration procedure. The NC3Rs project consists of recording clinical signs in acute 
inhalation studies and to develop and test a new system of scoring clinical signs in acute 
inhalation studies as a means of robustly identifying evident toxicity 
(http://www.nc3rs.org.uk/adoption-fixed-concentration-procedure-acute-inhalation-studies). 
 
Objective 2.2. Support the revision of current in vivo acute dermal toxicity test  
The OECD WNT recently approved a project proposal submitted by the UK to either revise or 
replace the OECD TG402 (acute dermal toxicity testing) in line with the 3Rs principles. The 
overall aim is to refine the testing for acute dermal toxicity and reduce the number of 
animals used. The current guideline requires the use of 5 animals per sex. If the refinements 
proposed are eventually accepted, OECD Guidance Document 24 (OECD, 2001d) would also 
need to be updated. 
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3. Conclusions 
This document presents EURL ECVAM's strategy on how to achieve 3Rs impact in the area of 
acute systemic toxicity assessment and testing. A number of objectives and related activities 
(not necessarily exhaustive) have been identified to achieve the stated strategic aims and 
ultimately change the way information requirements are satisfied for the different pieces of 
EU legislation (i.e. CLP, REACH, Biocidal and Plant Protection Products Regulations). One clear 
target is the implementation of the REACH Regulation and, in particular, the provision of 
acute systemic toxicity information requirements for low tonnage chemicals by the 2018 
registration deadline. 
EURL ECVAM is focusing its in-house activities on evaluating promising components of 
integrated approaches for testing and assessment, including the better use of alternative (in 
vitro and in silico) methods and on exploring the usefulness of existing data from other types 
of systemic toxicity studies. EURL ECVAM is also exploring the use of in silico models in 
route-to-route and in in vitro to in vivo extrapolations, and is supporting activities aimed at 
the refinement of in vivo studies through its participation in the EPAA. EURL ECVAM will 
continue evaluating test method submissions that address this regulatory endpoint in context 
of the strategy outlined here. 
Although EURL ECVAM is committed to play its role, the timely achievement of the objectives 
and aims presented here will depend on the proactive and coordinated engagement of 
multiple stakeholders.  
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Annex I Regulatory Requirements for Acute Systemic Toxicity 
 
Information on acute systemic toxicity represents a standard requirement within several 
pieces of chemicals legislation in the EU, as summarised in Table 3. The following 
sections illustrate the information requirements for acute systemic toxicity within the 
Regulations considered for the purpose of this report. 
 
1.1 Classification Labelling and Packaging 
The Regulation (EC) N° 1272/2008 on the classification, labelling and packaging of 
substances and mixtures (CLP Regulation, EU, 2008a), came into force on the 20th of 
January 2009 in all EU Member States and aligns previous EU legislation on 
classification, labelling and packaging of chemicals to the GHS (Globally Harmonised 
System of Classification and Labelling of Chemicals, UN, 2013). The CLP ensures that 
the hazards presented by chemicals are clearly communicated to workers and 
consumers in the EU through classification and labelling of chemicals. This Regulation 
applies, as a general principle, to all substances and mixtures supplied in the EU except 
to chemicals that are in the finished state intended for the final user: medicines, medical 
devices, cosmetics, veterinary medicines, food and feeding stuff such as food additives, 
food flavouring and feeding stuffs used in animal nutrition. 
The term acute toxicity describes the adverse effects observed following the oral or 
dermal administration of a single dose of a substance or a mixture, or multiple doses 
given within 24 hours, or an inhalation exposure of 4 hours. Therefore, the hazard class 
acute toxicity is differentiated into a) acute oral toxicity, b) acute dermal toxicity 
and c) acute inhalation toxicity.  
The CLP Regulation states (annex I, part 3, section 3.1.2.2.1): the preferred test species 
for evaluation of acute toxicity by the oral and inhalation routes is the rat, while the rat 
or rabbit are preferred for evaluation of acute dermal toxicity. When experimental data 
for acute toxicity are available in several animal species, scientific judgement shall be 
used in selecting the most appropriate LD50 value from among valid, well-performed 
tests. 
Based on acute toxicity values expressed as (approximate) LD50 (oral, dermal) or LC50 
(inhalation) values or as acute toxicity estimates (ATE), substances can be allocated to 
one of four toxicity categories according to the numeric criteria shown in Table 1. The 
acute toxicity label elements for hazard communication are shown in Table 2. Since 
experimental data may only be available for some of the ingredients of a mixture, 
specific guidance on classification of mixtures is provided in section 3.1.3 of the CLP 
Regulation. 
It is worth noting that for labelling purposes, the same pictogram (skull and crossbones) 
and signal word (danger) is used to communicate hazard categories 1 to 3. The hazard 
statement for categories 1 and 2 is the same (fatal). Prevention, response, storage and 
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disposal precautionary statements are usually the same for categories 1, 2 and 3. Only 
categories 1 and 2 for dermal and inhalation routes have more stringent prevention 
precautionary statements than category 3 (e.g. wear respiratory protection is not 
foreseen for category 3, see table 2).  
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Table 1. Acute toxicity hazard categories and acute toxicity estimates (ATE) defining the respective categories depending on 
the route of exposure (oral, dermal, inhalation) 
 
 
ORAL (mg/kg 
body weight) 
DERMAL 
(mg/kg body 
weight) 
INHALATION 
Gases [in parts per 
million per volume 
(ppmV)] 
Vapours* 
(mg/l) 
Dusts* and 
Mists* (mg/l) 
Category 
1 
ATE ≤ 5 ATE ≤ 50 ATE ≤ 100 ATE ≤ 0,5 ATE ≤ 0,05 
Category 
2 
5 < ATE ≤ 50 50 < ATE ≤ 200 100 < ATE ≤ 500 0,5 < ATE ≤ 2,0 
0,05 < ATE ≤ 
0,5 
Category 
3 
50 < ATE ≤ 
300 
200 < ATE ≤ 
1000 
500 < ATE ≤ 2500 
2,0 < ATE ≤ 
10,0 
0,5 < ATE ≤ 1,0 
Category 
4 
300 < ATE ≤ 
2000 
1000 < ATE ≤ 
2000 
2500 < ATE ≤ 
20000 
10,0 < ATE ≤ 
20,0 
1,0 < ATE ≤ 5,0 
 
*Dust: solid particles of a substance or mixture suspended in a gas (usually air); mist: liquid droplets of a substance or mixture 
suspended in a gas (usually air); vapour: the gaseous form of a substance or mixture released from its liquid or solid state. Dust is 
generally formed by mechanical processes. Mist is generally formed by condensation of supersaturated vapours or by physical shearing 
of liquids. Dusts and mists generally have sizes ranging from less than 1 to about 100 μm (CLP Regulation, section 3.1.2.1)  
 
 
 
 
  
 25 
Table 2.  Acute systemic toxicity label elements, i.e. pictograms, signal words, hazard statements and precautionary statements. 
 
Classification Category 1 Category 2 Category 3 Category 4 
GHS Pictograms 
    
Signal Word Danger Danger Danger Warning 
Hazard Statement:  
- Oral 
 
 
- Dermal 
 
 
- Inhalation 
 
H300: Fatal if 
swallowed  
 
H310: Fatal in 
contact with skin  
 
H330: Fatal if inhaled 
 
H300: Fatal if 
swallowed 
 
H310: Fatal in 
contact with skin 
 
H330: Fatal if 
inhaled 
 
H301: Toxic if 
swallowed 
 
H311: Toxic in 
contact with 
skin 
 
H331: Toxic if 
inhaled 
 
H302: Harmful 
if swallowed 
 
H312: Harmful 
in contact with 
skin 
 
H332: Harmful 
if inhaled 
Precautionary statement - 
Prevention 
- Oral 
 
P264, P270  
Precautionary statement - 
Prevention 
- Dermal 
 
P262, P264, P270, P280 
 
P280 
Precautionary statement - 
Prevention 
- Inhalation 
 
P260, P271, P284 
 
P261, P271 
Precautionary statement  - 
Response 
- Oral 
 
P301+P310, P321, P330 
 
P301+P312, 
P330 
Precautionary statement  - 
Response 
- Dermal 
 
P302+P350, P310, P322, P361, P363 
 
P302+P350, 
P310, P322, 
P363 
Precautionary statement  - 
Response 
- Inhalation 
 
P304+P340, P310, P320 
 
P304+P340, 
P312 
Precautionary statement - Storage 
- Oral 
 
P405 
 
 26 
 
- Dermal 
 
- Inhalation 
 
P405 
 
P403+P233, P405 
Precautionary statement - Disposal 
- Oral 
 
- Dermal 
 
P501 
 
P501 
Precautionary statement - Disposal 
- Inhalation 
P501  
P233: Keep container tightly close 
P260: Do not breathe dust/fume/gas/mist/vapours/spray 
P262: Do not get in eyes, on skin, or on clothing 
P264: Wash….thoroughly after handling 
P270: Do not eat, drink or smoke when using this product 
P271: Use only outdoors or in a well-ventilated area  
P280: Wear protective gloves/protective clothing/eye protection/face protection 
P284: Wear respiratory protection 
P301 + P310: If swallowed, immediately call a POISON CENTRE or doctor/physician  
P302 + P350: If on skin, gently wash with plenty of soap and water  
P304 + P340: If inhaled, remove victim to fresh air and keep at rest in a position comfortable for breathing 
P312: Call a POISON CENTER or doctor/ physician if you fell unwell 
P320: specific treatment is urgent (see…on this label) 
P321: specific treatment (see…on this label) 
P322: specific measures (see…on this label) 
P330: Rinse mouth 
P361: Remove/take off immediately all contaminated clothes  
P363: Wash contaminated clothes before reuse 
P403: Store in a well-ventilated place 
P405: Store locked up 
P501: Dispose of contents/container to…
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1.2 Chemicals 
Regulation (EC) N° 1907/2006 concerning the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH), was adopted in the EU to improve the protection of human 
health and the environment from the risks that can be posed by chemicals, while enhancing 
the competitiveness of the EU chemicals industry. It also promotes alternative methods for 
the hazard assessment of substances in order to reduce animal testing. REACH entered into 
force on the 1st of June 2007 (EU, 2006). Classification of substances is a mandatory part of 
the REACH registration process and, therefore, the CLP Regulation and the REACH Regulation 
are closely interlinked. 
The assessment of acute systemic toxicity is among the standard information requirements 
for substances manufactured or imported into the EU in quantities of 1 tonne or more per 
year (tpy) affecting, therefore, all chemicals registered under REACH. The standard 
information requirements for acute toxicity are tonnage triggered and are specified in 
Annexes VII and VIII as follows:  
 Annex VII (≥1 tpy): acute toxicity via the oral route of exposure is required. Column 2 of 
Annex VII details specific rules for adaptation of these information requirements, notably 
allowing for the waiving of acute oral toxicity testing if the substance is corrosive to the 
skin or if a study on acute toxicity by the inhalation route is available.  
 Annex VIII (≥ 10 tpy): as indicated in column 2 of Annex VIII - specific rules for 
adaptation: 
[par. 8.5]: in addition to the oral route, for substances other than gases, the 
information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other 
route. The choice for the second route will depend on the nature of the substance and 
the likely route of human exposure. If there is only one route of exposure, information 
for only that route needs to be provided. 
[par. 8.5.2]: testing by the inhalation route is appropriate if exposure of humans via 
inhalation is likely, taking into account the vapour pressure of the substance and/or 
the possibility of exposure to aerosols, particles or droplets of an inhalable size. 
[par. 8.5.3]: Testing by the dermal route is appropriate if: 
(1) inhalation of the substance is unlikely; and 
(2) skin contact in production and/or use is likely; and 
(3) the physicochemical and toxicological properties suggest the potential for a 
significant rate of absorption through the skin. 
Testing in animals does not need to be conducted in case there is available information to 
classify the substance for acute toxicity or the substance is classified as corrosive for the 
skin. In case testing is necessary, the in vivo methods accepted by regulatory bodies include 
the acute oral toxicity – fixed dose procedure [OECD TG420 (OECD, 2001a); EU B.1 bis (EU, 
2008b)], the acute oral toxicity – acute toxic class method [OECD TG423 (OECD, 2001b); EU 
B.1tris (EU, 2008b)], the acute oral toxicity – up-and-down procedure [OECD TG425 (OECD, 
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2001c)];  the acute dermal toxicity [OECD TG402 (OECD, 1987); EU B.3 (EU, 2008b)]; the 
acute inhalation toxicity [OECD TG403 (OECD, 2009a); EU B.2 (EU, 2014)] , the acute 
inhalation toxicity - acute toxic class method [OECD TG436 (OECD, 2009b]; EU B.52 (EU, 
2014).  
Annex I of the REACH Regulation describes how manufacturers and importers of substances 
have to assess and document that the hazards and potential risks from the substance they 
manufacture or import are controlled during manufacture and their own use(s) so that others 
further down the supply chain can adequately control the risks. For hazard assessment, a 
four step process is described that comprises the evaluation of non-human and human data, 
the classification and labelling of the substance and the calculation of Derived No-Effect 
Level (DNEL). The DNEL is defined as the level of exposure which should not be exceeded 
and is derived from all hazard information available on a substance (REACH Annex I, 1.0.1). 
Exposure levels of human populations can vary (for examples workers vs. general population) 
and should be compared to the appropriate DNEL to characterise the risk associated with 
exposures to a substance, taking into account the likely route(s) of exposure. For systemic 
acute effects, two DNELs (worker-DNEL acute inhalation and general population-DNEL acute 
inhalation) are normally required, although occupational inhalation exposure is often the 
most important one. Rarely, and on a case-by-case basis, the other routes may need to be 
assessed (potentially constituting three different DNELs). In terms of an acute toxicity DNEL, 
it has been proposed that the long-term DNEL is normally sufficient to set safe exposure 
levels for a substance 
(http://echa.europa.eu/documents/10162/13632/information_requirements_r8_en.pdf).  
However, if an acute toxicity hazard has been identified, an acute toxicity DNEL should be 
established for peak exposures, which may exceed the average daily exposures of long-term 
or acute DNELs. This is particularly relevant to workers, who may be exposed to a high 
concentration of a substance, for a short time period, for example when sampling from a 
vessel. 
Chemicals that are imported into or produced in the EU in quantities of 1 tonne or more per 
year per company have to be registered under REACH with a registration dossier. Several 
deadlines for registration have been set according to tonnage bands. By 2010 very toxic 
chemicals and those imported or produced at ≥ 1000 tpy had to be registered and by 31 
May 2013 chemicals imported or produced at 100 – 1000 tpy were registered. The final 
deadline for chemicals imported or produced in the Union at 1 – 100 tpy is the 31st of May 
2018. The number of registrations received by 31/10/2014 was 40229 corresponding to 
7992 unique substances (ECHA website http://echa.europa.eu/web/guest/information-on-
chemicals/registration-statistics). 
A precise indication of the likely number of new acute toxicity studies that are anticipated for 
the 2018 registration is not yet available. Pedersen et al. forecasted in 2003 around 22477 
phase-in substances2 in the tonnage band between 1 and 100 tpy. Comparing the estimates 
                                                        
2 Phase-in substances are substances that were already manufactured or placed on the market before 
REACH's entry into force 
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made for the 2010 and 2013 registration deadlines (2704 and 2461 substances, 
respectively) and the final outcome of both registrations (3400 and 2998 substances 
registered, respectively), and assuming that the same trend is maintain (~1.2 increase rate), 
one could expect around 26972 substances registered for the 2018 deadline. Moreover, 
according to the report prepared by Van der Jagt et al (2004) using a standard scenario that 
assumed possible use of QSARs, grouping, read across and options for waiving, it was 
forecasted that less than 5% of the phase-in substances would require testing on acute 
systemic toxicity (similar estimation for each route of exposure). The first ECHA report on the 
status of non-animal methods and alternative testing strategies used to generate 
information for registration purposes (Article 117(3) of REACH Regulation) showed that a 
substantial number of new in vivo studies were submitted to fill the data gaps for Annex VII 
and VIII endpoints that do not require testing proposals. In total, 1789 substances were 
considered by ECHA in the analysis carried out for this first report. Table 2 of the report 
shows that for acute toxicity, 486 new studies were identified: 211 by oral route, 114 by 
inhalation route and 161 by the dermal route, which would result in 13%, 6% and 9% of 
substances requiring new acute toxicity tests by the oral, inhalation and dermal route, 
respectively (ECHA, 2011). On the basis of all these assumptions, one could roughly estimate 
that for the next registration deadline no more than about 3500, 1600 and 2400 substances 
will require new information on acute oral, inhalation and dermal systemic toxicity, 
respectively. ECHA has published recently the second report (ECHA, 2014) that covered a 
total number of 3662 substances. Overall the number of new experimental studies has 
increased twice compared to the data published in 2011. In line with previous report most 
the of all new studies were submitted to fill in the data gaps for the Annex VII and VIII 
endpoints for which testing proposals were not required (among them acute systemic 
toxicity). From the new 1153 new acute toxicity studies identified with the date of 2009 or 
later, 464 were performed via the oral route, 468 via the dermal route and 221 via the 
inhalation route. 
 
1.3 Biocides 
The Biocidal Products Regulation (BPR, Regulation (EU) 528/2012) was adopted on the 22nd 
of May 2012 and came into force on the 1st of September 2013 (EU, 2012). It governs the 
toxicological testing, placing on the market, and use of biocidal products. Biocidal products 
contain active substances and are used to protect humans, animals, materials or articles 
from harmful organisms such as pests or bacteria. First and foremost the BPR aims to offer 
a high level of protection to humans and the environment. It also aims to harmonise the EU 
market as well as promote the reduction of animal testing by encouraging data sharing and 
the use of alternative testing methods.  
The information requirements for active substances and biocidal products are set out in 
Annexes II and III of the BPR, respectively. A detailed guidance on the application of these 
annexes and the preparation of the dossiers is available from the ECHA website 
(http://echa.europa.eu/documents/10162/15623299/biocides_guidance_information_require
ments_en.pdf). A stepwise approach for fulfilling information requirements is described in 
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this guidance document, where the first two steps comprise the gathering and analysis of all 
available information, such as physicochemical properties and QSAR predictions, on the 
active substance. Next, if necessary, guided by the information from the first two steps, new 
data is generated in the third step and in the final step this data is analysed (ECHA, 2013). 
Data requirements for active substances are reported as follows (Annex II, par. 8.7): 
 In addition to the oral route of administration (8.7.1), for substances other than gases, 
information mentioned under 8.7.2 to 8.7.3 shall be provided for at least one other route 
of administration.  
 The choice for the second route will depend on the nature of the substance and the likely 
route of human exposure. Gases and volatile liquids should be administered by the 
inhalation route. 
 If the only route of exposure is the oral route, then information for only that route need 
be provided. If either the dermal or inhalation route is the only route of exposure to 
humans then an oral test may be considered. Before a new dermal acute toxicity study is 
carried out, an in vitro dermal penetration study (OECD 428) should be conducted to 
assess the likely magnitude and rate of dermal bioavailability. 
 There may be exceptional circumstances where all routes of administration are deemed 
necessary. 
If a substance is classified as being corrosive to skin it does not need to be tested for acute 
toxicity (column 3 – specific rules for adaptation). 
By oral route (par. 8.7.1): 
 The Acute Toxic Class Method is the preferred method for the determination of this 
endpoint.  
Testing by the oral route is not necessary if the substance is a gas or a highly volatile 
substance (column 3 – specific rules for adaptation).  
With regard to the decision on the protocol to follow for this endpoint, the ECHA guidance 
document indicates that animal welfare issues should be taken into account and that the 
fixed dose procedure (i.e. OECD TG 420) should be considered as the first choice for testing 
(note that the information on the guidance document does not constitute legal advice). 
Inhalation route (par. 8.7.2.): Testing by the inhalation route is appropriate if human exposure 
is likely via inhalation, taken into account if:  
 the vapour pressure of the substance (a volatile substance has vapour pressure > 1 x 
10-2 Pa at 20 °C) and/or  
 the active substance is a powder containing a significant proportion (e.g. 1 % on a 
weight basis) of particles with particle size MMAD (Mass Median Aerodynamic 
Diameter) < 50 micrometers or  
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 the active substance is included in products that are powders or are applied in a 
manner that generates exposure to aerosols, particles or droplets of an inhalable size 
(MMAD <50 micrometers) 
 The Acute Toxic Class Method is the preferred method for the determination of this 
endpoint. 
The ECHA guidance document states that even if there is no information on particle/droplet 
size, an acute inhalation study should be performed where there is potential for exposure via 
inhalation from the use of biocidal products containing the active substance. With regard to 
the exposure conditions, the guidance specifies that unless whole body exposure is justified, 
only the head/nose of the animal should be exposed. In case the limit concentration of the 
test guideline or a maximum attainable concentration of the substance does not produce 
compound-related mortalities a full, three dose study may not be necessary (section 8.7.2 
ECHA Guidance on information requirements; ECHA, 2013). 
Dermal route (par. 8.7.3): Testing by the dermal route is necessary only if:  
 inhalation of the substance is unlikely, or  
 skin contact in production and/or use is likely, and either 
 the physicochemical and toxicological properties suggest potential for a significant rate 
of absorption through the skin, or  
 the results of an in vitro dermal penetration study (OECD 428) demonstrate high dermal 
absorption and bioavailability 
The ECHA guidance document specifies that new OECD validated tests for acute dermal 
toxicity should be taken into account once available and similarly validated non-animal 
methods should be consulted. For substances with low acute dermal toxicity a limit test with 
2000 mg/kg body weight may be sufficient (section 8.7.3 ECHA Guidance on information 
requirements; ECHA, 2013). 
Information requirements for biocidal products are reported as follows (Annex III):  
 (par. 8.5): Classification using the tiered approach to classification of mixtures for acute 
toxicity in Regulation (EC) No 1272/2008 is the default approach.  
 (par. 8.5; column 3 – specific rules for adaptation) Testing on the biocidal 
product/mixture does not need to be conducted if there are valid data available on each 
of the components in the mixture to allow classification according to the rules laid down 
in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and synergistic effects 
between any of the components are not expected. 
 (par. 8.5.4): For biocidal products that are intended to be authorised for use with other 
biocidal products, the risks to human health, animal health and the environment arising 
from the use of these product combinations shall be assessed. As an alternative to acute 
toxicity studies, calculations can be used. In some cases, for example where there are no 
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valid data available of the kind set out in column 3, this may require a limited number of 
acute toxicity studies to be carried out using combinations of the products. 
 (par. 8.5.4; column 3 – specific rules for adaptation): Testing on the mixture of products 
does not need to be conducted if there are valid data available on each of the 
components in the mixture to allow classification of the mixture according to the rules 
laid down in Directive 1999/45/EC and Regulation (EC) No 1272/2008 (CLP), and 
synergistic effects between any of the components are not expected. 
 
1.4 Plant Protection Products 
The Regulation (EC) N° 1107/2009 concerns the placing of plant protection products (PPPs) 
on the market (EU, 2009a). It came into force on the 21st of October 2009. PPPs describe a 
range of products such as insecticides, fungicides and plant growth regulators that are 
applied to plants and crops before and/or after their harvest in order to protect and preserve 
them. Maximum pesticide residues levels that may be present in food are regulated by 
Regulation (EC) No 396/20053 and fall outside the scope of this document. PPPs contain 
active substances that have to be tested in terms of their safety for human health, animal 
health and the environment. Active substances that are deemed to be safe are placed on an 
EU list and Member states may authorise only PPPs that contain active substances from this 
list.  
The data requirements for the active substances of PPPs are set out in Commission 
Regulation (EU) N° 283/2013 that came into effect on the 1st of March 2013 (EU, 2013a). In 
terms of acute toxicity testing, section 5.2 states the following: 
The studies, data and information to be provided and evaluated shall be sufficient to 
permit the identification of effects following a single exposure to the active substance, 
and in particular to establish, or indicate: 
a. the toxicity of the active substance;  
b. the time course and characteristics of the effect with full details of 
behavioural changes and possible gross pathological findings at post-mortem; 
c. the possible need to consider establishing acute reference doses (such as the 
acute reference dose [ARfD], the acute acceptable operator exposure level 
[AOEL]); 
d. where possible the mode of toxic action; and  
e. the relative hazard associated with the different routes of exposure. 
The ARfD of a pesticide describes the amount that can be ingested by humans in a period of 
24 hours or less without any appreciable health risk (Yoshida et al., 2013). Ideally, an ARfD 
would be set based on an acute toxicity study, however these studies only provide limited 
                                                        
3 REGULATION (EC) NO 396/2005 of the European Parliament and of the Council of 23 February 2005 on 
maximum residue levels of pesticides in or on food and feed of plant and animal origin and amending 
Council Directive 91/414/EEC 
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information. In order to avoid carrying out another toxicity study, the NOAEL value for a 
relevant endpoint of a repeated dose toxicity study is mostly used to set an ARfD. For 
example, reproductive and developmental toxicity, acute neurotoxicity and haematotoxicity 
studies have been shown to provide relevant information for setting ARfD values (Yoshida et 
al., 2013, Solecki et al., 2005). An appropriate safety factor (ranging from 10 – 100) is then 
applied to the NOAEL value to set the ARfD (Solecki et al., 2005). 
The information should allow classification of the substance in accordance with the CLP 
Regulation (EC N° 1272/2008). The information generated is of particular value in assessing 
hazards likely to arise in accident situations. All available data that is relevant for the 
assessment of the toxicological profile of the active substance such as physicochemical 
properties, biological data and structure-activity relationships of chemical analogues shall be 
provided. Only validated methods that are specific to the endpoint under investigation should 
be used in the toxicity studies. 
The use of non-animal test methods and other risk assessment strategies is promoted in 
order to keep the number of animals used for testing to a minimum and to use animal 
testing as a last resort. 
Circumstances in which oral route is required (par. 5.2.1): 
The acute oral toxicity of the active substance shall always be reported.  
Circumstances in which dermal route is required (par. 5.2.2): 
Acute dermal toxicity studies need to be reported, unless waiving is scientifically justified, for 
example where oral LD50 is greater than 2000 mg/kg. Both local and systemic effects need to 
be investigated. Findings of severe skin irritation or corrosion in the dermal study may be 
used instead of performing a specific irritation study. 
Circumstances in which inhalation route is required (par. 5.2.3): 
Acute inhalation toxicity studies are required where any of the following apply: 
a) the active substance has a vapour pressure > 1 × 10 –2 Pa at 20 °C; 
b) the active substance is a powder containing a significant proportion of particles of a 
diameter < 50 μm ( > 1 % on weight basis); 
c) the active substance is included in products that are powders or are applied by 
spraying. 
The head/nose only exposure shall be used, unless whole body exposure can be justified. 
The data requirements for plant protection products are set out in Commission Regulation 
(EU) N° 284/2013 that came into effect on the 1st of March 2013 (EU, 2013b). Information 
on acute toxicity shall be provided. The Regulation states that the relevant calculation 
methods used for the classification of mixtures as laid down in Regulation (EC) N° 
1272/2008 shall, where appropriate, be applied in the hazard assessment of the plant 
protection product.  
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1.5 Cosmetics 
Regulation (EC) N° 1223/2009 on cosmetic products came into force in December 2009 and 
is fully applicable since the 11th of July 2013 (EU, 2009b). According to Article 1, the 
Regulation establishes rules to be complied with by any cosmetic product made available on 
the market, in order to ensure the functioning of the internal market and a high level of 
protection of human health. Since coming into force, the Regulation prohibits (article 18) the 
placing on the market of: 
 cosmetic products where the final formulation has been the subject of animal testing; 
 cosmetic products containing ingredients or combinations of ingredients which have 
been the subject of animal testing.  
When a cosmetic product is placed on the market a product information file should be 
available and shall contain a cosmetic product safety report, which in turn shall contain as a 
minimum the cosmetic product safety information and safety assessment (Annex I of 
Regulation (EC) N° 1223/2009). With regard to safety information, Annex I of the legal text 
states that the report shall contain without prejudice to Article 18 (animal testing), the 
toxicological profile of substance contained in the cosmetic product for all relevant 
toxicological endpoints. A particular focus on local toxicity evaluation (skin and eye irritation), 
skin sensitisation, and in the case of UV absorption photo-induced toxicity shall be made. It 
also states that particular consideration shall be given to any possible impacts on the 
toxicological profile due to particle sizes, including nanomaterials, impurities of the 
substances and raw material used, and interaction of substances. 
In the EU, two channels function with respect to the safety evaluation of cosmetic 
substances (SCCS, 2012). It is primarily the substances listed in Annexes II, III, IV, V and VI of 
the cosmetics Regulation that fall under the responsibility of the Scientific Committee on 
Consumer Safety (SCCS). All ingredients of cosmetic products other than the substances 
present in the Annexes, is the responsibility of the “responsible person”, as defined by the 
Regulation through the safety assessor. In general, the safety evaluation of cosmetic 
substances by the SCCS is based on the principles and practice of the risk assessment 
process (WHO 2001; European Commission 2000) usually applied for ingredients in 
medicinal products, plant protection products, food additives. 
Acute toxicity is part of the minimal base set requirements that a dossier of a cosmetic 
substance should include if submitted for evaluation to the SCCS (SCCS, 2012).  
For all other potential ingredients of cosmetic products outside the Annexes some general 
toxicological requirements apply. Several cosmetic substances belong to the category of 
chemical substances EU produced/imported at levels between 1 and 10 tonnes per year. 
Therefore a sound safety evaluation should at least include REACH data requirements under 
ANNEX VII (e.g. acute toxicity via the oral route). 
Cosmetic products containing substances that have been subject to acute toxicity testing 
after 11 March 2009 to meet the requirements of the Cosmetic Regulation, are not allowed 
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on the EU market (SCCS, 2012). This also includes information available from experiments 
carried out to meet the requirements of the Cosmetic Regulation that have been carried out 
before the Regulation became applicable. The majority of ingredients used in cosmetic 
products are also used in many other consumer and industrial products. In this regard, acute 
toxicity data of cosmetic substances are usually available as a result of compliance with the 
provisions of other EU Regulations, e.g. the CLP Regulation (EU, 2008a) and REACH 
requirements (EU, 2006). Although the data available in these cases may have been 
generated in animals, they should not trigger marketing ban, since they have not been 
generated to meet the requirements of the Cosmetic Regulation.  
According to the Impact Assessment on the Animal Testing Provisions in Regulation (EC) 
1223/2009 on Cosmetics, acute toxicity plays in practice a limited role for the cosmetics 
industry. Ingredients used in this sector essentially do not raise the risk of acute toxicity and 
sufficient information is often available from repeated dose studies. 
(http://ec.europa.eu/consumers/sectors/cosmetics/files/pdf/animal_testing/ia_at_2013_en.pdf). 
 
1.6 Pharmaceuticals – ICH Guideline 
The ICH guidance on non-clinical safety studies for the conduct of human clinical trials and 
marketing authorisation for pharmaceuticals [ICH M3(R2)], came into effect in December 
2009 (ICH, 2009). This guideline aims to harmonise the testing requirements between 
Europe, the US and Japan, further implement the principles of the 3Rs and promote the safe 
and ethical development of new pharmaceutical agents. The testing strategies for the 
pharmaceutical agents under study should be guided by scientific and ethical principles and 
may need to be adapted for the specific type of agent under study. Non-clinical safety 
studies should be adequate to identify the toxic potential of a substance and to aid the 
identification of an initial safe starting dose for human trials. 
Information on acute toxicity of pharmaceutical compounds used to be obtained from single 
dose toxicity studies in two mammalian species using both the clinical and a parenteral route 
of exposure. However, it has been realised that such information can be obtained from 
appropriately conducted dose-escalation studies or short-duration dose-ranging studies that 
define a maximum tolerated dose in the general toxicity test species (Robinson et al., 2008). 
If this acute toxicity information is available, no additional single dose acute toxicity studies 
are recommended thus reducing the overall number of studies and animals used. For 
example, appropriately conducted dose escalation studies or short duration dose-ranging 
studies that define a maximum tolerated dose in the general toxicity test species can provide 
information on acute toxicity. In all cases a dose of 1000 mg/kg/day in rodent and non-
rodent species is considered an appropriate limit dose. Studies can be limited to the clinically 
relevant route only and data can be obtained from non-GLP studies if clinical administration 
is supported by GLP repeated dose toxicity studies. Lethality should not be an intended 
endpoint in studies assessing acute toxicity. In some cases, such as exploratory clinical 
studies, the acute toxicity or single dose studies can be the primary support for single dose 
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studies in humans, in which case the high dose selection can be different from that 
described above but should be adequate to support the intended clinical route and dose. 
With regard to pharmaceuticals for veterinary use, Directive 2009/9/EC lays down the data 
requirements for marketing authorisation applications for veterinary medicinal products. Part 
3 of Directive 2009/9/EC, on safety and residues tests, indicates that single dose toxicity 
studies may be used to predict possible effects of acute overdosage in the target species, 
possible effects of accidental administration to humans and to provide information on the 
doses to be used in repeat dose studies. Single-dose toxicity studies should reveal the acute 
toxic effects of the substance and the time course for their onset and remission. The studies 
to be carried out shall be selected with a view to providing information on user safety, e.g. if 
substantial exposure by inhalation or dermal contact of the user of the veterinary medicinal 
product is anticipated, those routes of exposure shall be studied. Only minimal additional 
guidance is available.  
The Committee for Medicinal Products for Veterinary Use (CVMP) guideline on user safety for 
pharmaceutical veterinary medicinal products highlights that, in relation to user safety, 
toxicity data from published literature or from toxicity studies may be used 
(EMA/CVMP/543/03-Rev.1).  
In addition, the CVMP guideline on safety and residue data requirements for veterinary 
medicinal products intended for minor uses or minor species (MUMS) compares the data 
requirements for standard applications and those for MUMS applications. In relation to 
standard applications the document indicates that data from two mammalian species would 
normally be expected but that one species may be the target species, and that data from 
two routes of administration would normally be expected. The document also indicates that 
“to reduce animal numbers, alternative validated protocols and internationally recognised 
protocols will be accepted” (EMEA/CVMP/SWP/66781/2005) 
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Table 3. Overview of the EU legislations considered in the context of this report and their information requirements for acute systemic 
toxicity. 
 
EU Regulation Application Information requirements Method of choice 
CLP Regulation (EC) 
N°1272/2008 on the 
classification, labelling 
and packaging of 
substances and mixtures. 
CLP aligns previous EU 
legislation to the GHS.  
All substances and 
mixtures supplied in the 
EU except to chemicals in 
the finished state 
intended for the final 
users. All substances 
subject to REACH are also 
subject to classification, 
even those not placed on 
the market if they are 
subject to registration or 
notification. 
Hazard assessment and appropriate 
labelling.  
Hazard class acute toxicity is 
differentiated into acute oral, dermal and 
inhalation toxicity. For each route of 
exposure it allows classification into four 
hazard categories based on acute toxicity 
values or acute toxicity estimates. 
Oral route: Fixed dose procedure 
(OECD TG 420; EU B.1 bis); Acute 
toxic class method (OECD TG 423; 
EU B.1tris); Up-and-down procedure 
(OECD TG 425);   
Dermal route: the acute dermal 
toxicity (OECD TG 402; EU B.3);  
Inhalation route: the acute 
inhalation toxicity (OECD TG 403; EU 
B.2); Acute Toxic class method 
(OECD TG 436) 
REACH Regulation (EC) 
N° 1907/2006 concerning 
the Registration, 
Evaluation, Authorisation 
and Restriction of 
Chemicals. 
Acute systemic toxicity is 
mandatory for 
substances manufactured 
or imported in the EU in 
quantities of 1 tonne or 
more (i.e. all chemicals 
registered under REACH).  
Standard information 
requirements are tonnage 
triggered: 
Testing via the oral route 
is requested for 
substances in the 
tonnage ban 1-10 tpy. 
Hazard assessment 
A DNEL for acute toxicity should be 
derived if an acute toxicity hazard 
(leading to classification and labelling) 
has been identified and there is a 
potential for high peak exposures. High 
peak exposures are usually assessed for 
the inhalation route only. 
Oral route: Fixed dose procedure 
(OECD TG 420; EU B.1 bis); Acute 
toxic class method (OECD TG 423; 
EU B.1tris); Up-and-down procedure 
(OECD TG 425);   
Dermal route: the acute dermal 
toxicity (OECD TG 402; EU B.3);  
Inhalation route: the acute 
inhalation toxicity (OECD TG 403; EU 
B.2); Acute Toxic class method 
(OECD TG 436) 
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For substances imported 
or produced in quantities 
above 10 tpy, information 
for at least one other 
route in addition to the 
oral route is requested. 
Biocides Regulation 
(EU) 528/2012 governs 
the toxicological testing, 
placing on the market, 
and use of biocidal 
products. 
All biocidal products and 
active substances 
marketed in EU 
independent of the 
tonnage level. 
Hazard assessment 
For substances other than gases, 
information on acute oral toxicity and at 
least one additional route of exposure is 
required for both active substances 
contained in biocidal products and the 
final product. 
Oral route: the acute toxic class 
method (OECD TG 423; EU B.1tris) is 
the preferred method. 
Dermal route: the acute dermal 
toxicity (OECD TG 402; EU B.3). 
Inhalation route: the acute toxic 
class method (OECD TG 436) is the 
preferred method. 
For biocidal products, the tiered 
approach to classification of 
mixtures for acute toxicity in CLP 
Regulation is the default approach. 
In the case of product combinations 
and if data are available in each of 
the components, calculations are 
possible. 
Plant Protection 
product Regulation (EC) 
N° 1107/2009 concerning 
the placing of plant 
protection products in the 
market 
Regulations (EU) 
283/2013 and (EU) No 
All plant protection 
products and active 
substances marketed in 
EU independent of 
tonnage level. 
 
Hazard assessment  
Information requirement for acute 
toxicity is mandatory for both active 
substances contained in PPPs and the 
final product.  
For final product relevant calculation 
methods used for the classification of 
mixtures as laid down in REACH can be 
Oral route: Fixed dose procedure 
(OECD TG 420; EU B.1 bis); Acute 
toxic class method (OECD TG 423; 
EU B.1tris); Up-and-down procedure 
(OECD TG 425);   
Dermal route: the acute dermal 
toxicity (OECD TG 402; EU B.3);  
Inhalation route: the acute 
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284/2013 set out the 
data requirements for 
active substances and 
plant protection products 
(PPPs), respectively, in 
accordance with 
Regulation (EC) N° 
1107/2009. 
applied if appropriated.   
For active substances acute oral toxicity 
is always required; dermal toxicity unless 
waiving is scientifically justified and 
inhalation toxicity only if some 
quantitative criteria are met. 
inhalation toxicity (OECD TG 403; EU 
B.2); Acute Toxic class method 
(OECD TG 436) 
Cosmetics Regulation 
(EC) N° 1223/2009 
All cosmetic ingredients 
independent of tonnage 
level. 
Acute toxicity is part of 
the minimal base set 
requirements. 
 
According to the Impact Assessment on 
the Animal Testing Provisions in 
Regulation (EC) 1223/2009 on Cosmetics, 
acute toxicity plays in practice a limited 
role for the cosmetics industry. 
Ingredients used in this sector essentially 
do not raise the risk of acute toxicity and 
sufficient information is often available 
from repeated dose studies. 
Alternative non-animal methods 
validated and adopted at 
Community level. 
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